Methylphenidate

Chemical formula: C₁₄H₁₉NO₂  Molecular mass: 233.306 g/mol  PubChem compound: 4158

Therapeutic indications

Methylphenidate is indicated for:

Attention deficit hyperactivity disorder

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 - 65 years old)

Methylphenidate is indicated as part of a comprehensive treatment programme for Attention Deficit Hyperactivity Disorder (ADHD) in children aged 6 years of age and over when remedial measures alone prove insufficient.

Treatment must be initiated and supervised by a physician specialised in the treatment of ADHD such as an expert paediatrician or a child and adolescent psychiatrist.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Methylphenidate is contraindicated in the following cases:

Glaucoma

Glaucoma

Phaeochromocytoma

Phaeochromocytoma

Non-selective, irreversible monoamine oxidase (MAO) inhibitors

Non selective Monoamine Oxidase Inhibitors and additionally not Reversible inhibitors of monoamine oxidase A (RIMAs)

Hyperthyroidism, thyrotoxicosis

at least one of
Hyperthyroidism
Thyrotoxicosis

Severe depression, anorexic disorders, psychotic symptoms, personality disorder

at least one of
Severe depression
H/O: depression
Anorexia nervosa
H/O: anorexia nervosa
Suicidal intent
History of attempted suicide
Psychotic symptom present
Mood disorder
History of mood disorder
Schizophrenia
H/O: schizophrenia
Antisocial personality disorder

Severe and episodic bipolar disorder

at least one of
Bipolar type I disorder currently in full remission
H/O: manic depressive disorder

Cardiovascular disorders

Cardiovascular disorder

Cerebrovascular disorders

at least one of
Cerebrovascular disease
Cerebral aneurysm
Vasculitis
CVA - Cerebrovascular accident

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2022: CONCERTA Extended-release tablet
Structured Product Labeling (SPL/PLR) 2020: RITALIN Tablet
Summary of Product Characteristics (SPC) 2023: MATORIDE XR Prolonged-release tablet
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈